Skip to main content
Journal cover image

Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Publication ,  Journal Article
Lepore, JJ; Olson, E; Demopoulos, L; Haws, T; Fang, Z; Barbour, AM; Fossler, M; Davila-Roman, VG; Russell, SD; Gropler, RJ
Published in: JACC Heart Fail
July 2016

OBJECTIVES: This study sought to determine if glucagon-like peptide (GLP)-1 ameliorates myocardial metabolic abnormalities in chronic heart failure. BACKGROUND: Albiglutide (GSK716155) is a GLP-1 agonist indicated for type 2 diabetes. METHODS: We performed a randomized, placebo-controlled study evaluating 12 weeks of albiglutide in New York Heart Association II or III subjects with ejection fraction <40%. Subjects received weekly placebo (n = 30) or albiglutide 3.75 mg (n = 12), 15 mg (n = 13), or 30 mg (n = 27). The primary comparison was between albiglutide 30 mg and placebo. Assessments included echocardiography, 6-minute-walk test, and peak oxygen consumption. In a subgroup of patients, myocardial glucose and oxygen use were assessed. Endpoints are reported as change from baseline ± SE. RESULTS: Albiglutide 30 mg compared with placebo did not improve change from baseline in left ventricular ejection fraction (2.4% [1.1%] vs. 4.4% [1.1%]; p = 0.22), 6-min walk test (18 [12] m vs. 9 [11] m; p = 0.58), myocardial glucose use (p = 0.59), or oxygen use (p = 0.25). In contrast, albiglutide 30 mg versus placebo improved change from baseline in peak oxygen consumption (0.9 [0.5] ml/kg/min vs. -0.6 [0.5] ml/kg/min; p = 0.02). Albiglutide was well tolerated. CONCLUSIONS: Although there was no detectable effect of albiglutide on cardiac function or myocardial glucose use, there was a modest increase in peak oxygen consumption, which could have been mediated by noncardiac effects. (A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure; NCT01357850).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

July 2016

Volume

4

Issue

7

Start / End Page

559 / 566

Location

United States

Related Subject Headings

  • Walk Test
  • Stroke Volume
  • Radiopharmaceuticals
  • Quality of Life
  • Positron Emission Tomography Computed Tomography
  • Oxygen Consumption
  • Myocardium
  • Middle Aged
  • Male
  • Incretins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lepore, J. J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A. M., … Gropler, R. J. (2016). Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC Heart Fail, 4(7), 559–566. https://doi.org/10.1016/j.jchf.2016.01.008
Lepore, John J., Eric Olson, Laura Demopoulos, Thomas Haws, Zixing Fang, April M. Barbour, Michael Fossler, Victor G. Davila-Roman, Stuart D. Russell, and Robert J. Gropler. “Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.JACC Heart Fail 4, no. 7 (July 2016): 559–66. https://doi.org/10.1016/j.jchf.2016.01.008.
Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2016 Jul;4(7):559–566.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

July 2016

Volume

4

Issue

7

Start / End Page

559 / 566

Location

United States

Related Subject Headings

  • Walk Test
  • Stroke Volume
  • Radiopharmaceuticals
  • Quality of Life
  • Positron Emission Tomography Computed Tomography
  • Oxygen Consumption
  • Myocardium
  • Middle Aged
  • Male
  • Incretins